Enanta Pharma (ENTA) Misses Q1 EPS Views

Enanta Pharma (NASDAQ: ENTA) reported Q1 EPS of $2.18, $1.64 worse than the analyst estimate of $3.82. Revenue for the quarter came in at $77.5 million versus the consensus estimate of $84.1 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat